Comparative Pharmacology
Head-to-head clinical analysis: BENZAMYCIN versus CLEOCIN T.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZAMYCIN versus CLEOCIN T.
BENZAMYCIN vs CLEOCIN T
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZAMYCIN (benzoyl peroxide and clindamycin) combines the keratolytic and antimicrobial actions of benzoyl peroxide with the antibacterial effect of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It exhibits bacteriostatic activity against susceptible organisms.
Topical: Apply a thin layer to affected areas twice daily (morning and evening). Each gram contains 30 mg benzoyl peroxide and 30 mg erythromycin.
Apply a thin film of 1% solution or gel twice daily to affected skin areas.
None Documented
None Documented
2.5-3.5 hours in adults with normal renal function; may be prolonged to 4-6 hours in patients with hepatic impairment
The terminal elimination half-life in adults with normal renal and hepatic function is approximately 2-3 hours. In severe hepatic impairment, half-life may increase to 5-6 hours. No significant alteration in renal impairment.
Renal excretion: ~70% (30% as unchanged drug, 40% as active metabolite N-desmethylclindamycin); biliary/fecal: ~30%
Clindamycin is primarily eliminated via hepatic metabolism and biliary excretion. Approximately 10% of the active drug is excreted renally, with the remainder as inactive metabolites in feces (biliary/fecal route).
Category C
Category C
Topical Antibiotic
Topical Antibiotic